Tirzepatide is also under investigation for the reduction of morbidity and mortality in people with obesity and overweight without diabetes (NCT05556512)
Removing the prefilled pen from refrigeration while you prepare your injection site gives the medication time to warm naturally without affecting its stability or potency
Currently, there is an ongoing randomised double-masked placebo-controlled trial, the SUMMIT trial, studying the efficacy and safety of tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide and GLP-1 receptors, versus placebo in HFpEF patients with obesity (NCT04847557)
Does not contain: Parabens, sulfates, perfumes, mineral oil, artificial preservatives and colours, gluten or dairy
AD is the most common cause of dementia which is characterized by progressive cognitive decline and neurodegeneration